Taysha Gene Therapies Announces Presentations at the Upcoming 29th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT)
10/06/2022 - 07:00 AM
DALLAS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced two poster presentations at the upcoming 29th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT) in cooperation with the British Society of Gene & Cell Therapy (BSGCT) taking place in Edinburgh, Scotland from October 11-14, 2022. Poster Presentation Details
P238: Assessment of Safety and Biodistribution of a miniMECP2 AAV9 Vector for Gene-replacement Therapy of Rett Syndrome in Non-human Primates (NHPs) Presenter – Dirk Schmitt, Senior Director of Medical Affairs, Taysha Gene Therapies Date and Time – Thursday, October 13th at 17:30 GMT + 1/12:30 PM Eastern Time Location – Cromdale Hall P206: Assessment of Safety of miniMECP2 AAV9 vector (TSHA-102) for Gene-replacement Therapy of Rett Syndrome in Rats Presenter – Dirk Schmitt, Senior Director of Medical Affairs, Taysha Gene Therapies Date and Time – Thursday, October 13th at 17:30 GMT + 1/12:30 PM Eastern Time Location – Cromdale Hall Additional details can be found at the ESGCT 29th Annual Meeting website . About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com . Company Contact: Kimberly Lee, D.O. Chief Corporate Affairs Officer Taysha Gene Therapiesklee@tayshagtx.com Media Contact: Carolyn Hawley Evoke Canalecarolyn.hawley@evokegroup.com
Taysha Gene Therapies Inc
TSHA Rankings
#681 Ranked by Stock Gains
TSHA Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology
About TSHA
taysha gene therapies, inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. it primarily develops tsha-101 for the treatment of gm2 gangliosidosis; tsha-118 for the treatment of cln1 disease; tsha-102 for the treatment of rett syndrome; tsha-103 for the treatment of slc6a1 haploinsufficiency disorder; and tsha-104 for the treatment for surfeit locus 1 deficiency. the company also has strategic partnership with the university of texas southwestern medical center to develop and commercialize transformative gene therapy treatments. taysha gene therapies, inc. was founded in 2019 and is based in dallas, texas.